STEHIGH SIGNALFINANCIAL10-K

STERIS completed its Dental segment divestiture, driving a 62.5% surge in net income to $614.6M while substantially reducing total debt by 38.5% to $1.9B.

The completed divestiture has fundamentally transformed STERIS's financial profile, generating significant proceeds that enabled massive debt reduction and a 17x increase in share buybacks to $211.3M. Management's updated language reflects improved supply chain conditions and cost pressures moderating in fiscal 2025, suggesting the company has successfully navigated prior operational headwinds.

Comparing 2025-05-29 vs 2024-05-29View on EDGAR →
FINANCIAL ANALYSIS

STERIS delivered exceptional financial performance driven by its Dental segment divestiture, with net income surging 62.5% to $614.6M and operating cash flow growing 18% to $1.1B. The company used divestiture proceeds strategically, reducing total debt by 38.5% to $1.9B while dramatically increasing share buybacks from $11.8M to $211.3M, though cash reserves declined 31% to $220.5M. Overall, the financial picture signals a successful portfolio optimization that has strengthened the balance sheet, improved profitability, and positioned the company to return significant capital to shareholders.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+1696.2%
$11.8M→$211.3M

Share repurchases increased 1696.2% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+62.5%
$378.2M→$614.6M

Net income grew 62.5% — bottom-line growth signals improving overall business health.

Total Debt
Balance Sheet
-38.5%
$3.1B→$1.9B

Debt reduced 38.5% — deleveraging strengthens balance sheet and reduces financial risk.

Interest Expense
P&L
+33.7%
$108.0M→$144.4M

Interest expense surged 33.7% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
-31%
$319.6M→$220.5M

Cash declined 31% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-30.3%
$2.9B→$2.0B

Current assets declined 30.3% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
-25.6%
$4.7B→$3.5B

Liabilities reduced 25.6% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+18%
$973.3M→$1.1B

Operating cash flow grew 18% — strong conversion of earnings to cash, healthy business fundamentals.

Inventory
Balance Sheet
-13.8%
$674.5M→$581.3M

Inventory reduced 13.8% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2025-05-29
PRIOR — 2024-05-29
ADDED
Previously, we had four reportable business segments; however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations.
Historical information has been retrospectively adjusted to exclude discontinued operations for comparability, as required.
Our products include pharmaceutical detergen ts, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators.
INFORMATION WITH RESPECT TO OUR BUSINESS IN GENERAL Sources and Availability of Raw Materials.
We have long-term supply contracts for certain materials for which there are few suppliers, or those that are single-sourced in certain regions of the world, such as ethylene oxide ("EO") and radioisotope cobalt-60 ("cobalt-60"), which are necessary to our AST operations.
+7 more — sign up free →
REMOVED
Previously, we had four reportable business segments; however, as a result of the agreement to divest our Dental segment, Dental is presented as discontinued operations.
Historical information has been retrospectively adjusted to reflect these changes for comparability, as required.
These products include pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators.
However, in fiscal 2023 and 2024 we experienced delays in receiving materials and significant cost increases.
Our supply chain challenges eased during the second half of fiscal 2024 and we do not currently expect significant disruption to our operations due to sourcing delays in fiscal 2025.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →